Approach to Breast Cancer Treatment in Elderly Patients

tibbi onkoloji ozel 13-4 kapak

Selçuk ŞEBERa, Devrim ÇABUKb, Gül BAŞARANc
aTekirdağ Namık Kemal Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji BD, Tekirdağ, TÜRKİYE
bKocaeli Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji BD, Kocaeli, TÜRKİYE
cAcıbadem Mehmet Ali Aydınlar Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji BD, İstanbul, TÜRKİYE
ABSTRACT
“Old age” should be carefully evaluated before the treatment of all kinds of diseases, not only chronologically but also in functional terms. Regardless of the stage of breast cancer, it is known that older patients benefit from standard treatments as much as younger patients to the extent that they are represented in clinical trials, but we also know that toxicity is augmented in this age group. The elderly patient group is a very heterogeneous group within itself, and it is important to separate the healthier, more fit elderly group who will benefit from standard treatments from the group that can only receive standard treatment with some rehabilitation. In addition, it is one of the most important duties of the clinician to identify patients who cannot tolerate both standard and modified treatments before initiation of the cancer treatment. Today, although there are several Comprehensive Geriatric Evaluation tools which are developed for aiding the clinician for making treatment decisions , most of the elderly patients are not properly evaluated in the busy day to day clinical practice . As an alternative ,parameters such as patients daily work, social enviorment, prescirbed medicines for other comorbidities , and the potential side effects of the recommended treatment should be carefully reviewed. The validity of the treatment decisions taken at the start of the treatment should be re-evaluated at each visit and if necessary, modifications should be made to maximize benefit with the least toxicity.

Keywords: Elderly;breast cancer;treatment

Referanslar

  1. Tesarova p. Specific Aspects of Breast Cancer Therapy of Elderly Women. BioMed Research International 2016;(2016):1381695. [Crossref]  [PubMed]  [PMC]
  2. Aapro M, Wildiers h. Triple-negative breast cancer in the older population. Ann Oncol 2012;23 Suppl 6:vi52-5 [Crossref]  [PubMed]
  3. Noone AM, Cronin KA, Altekruse SF, howlader N, Lewis DR, petkov vI, et al. Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results program, 1992-2013. Cancer Epidemiol Biomarkers prev. 2017;26(4):632-41. [Crossref]  [PubMed]  [PMC]
  4. Cronin KA, Lake Aj, Scott S, Sherman RL, Noone AM, howlader N, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124(13):2785-800. [Crossref]  [PubMed]  [PMC]
  5. Extermann M, Aapro M, Bernabei R, Cohen hj, Droz jp, Lichtman S, et al; Task Force on CGA of the International Society of Geriatric Oncology. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol hematol. 2005;55(3):241-52. [Crossref]  [PubMed]
  6. Decoster L, van puyvelde K, Mohile S, Wedding U, Basso U, Colloca G,et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26(2):288-300. 7. [Crossref]  [PubMed]
  7. Mohile SG, Dale W, Somerfield MR, hurria A. practical Assessment and Management of vulnerabilities in Older patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary. j Oncol pract. 2018; 14(7):442. [Crossref]  [PubMed]  [PMC]
  8. National Comprehensive Cancer Network. NCCN Clinical practice Guidelines in Oncology. Older adult oncology. (Accessed on May 15, 2019). [Link]
  9. Freyer G, Geay jF, Touzet S, provencal j, Weber B, jacquin jp, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16(11):1795-800. [Crossref]  [PubMed]
  10. Ramjaun A, Nassif MO, Krotneva S, huang AR, Meguerditchian AN. Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. j Geriatr Oncol. 2013;4(3):271-81. [Crossref]  [PubMed]
  11. hamaker ME, prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. Leuk Res. 2014;38(3):275- 83. [Crossref]  [PubMed]
  12. Corre R, Greillier L, Le Caër h, Audigier-valette C, Baize N, Bérard h, et al. Use of a Comprehensive Geriatric Assessment for the Management of Elderly patients With Advanced Non-Small-Cell Lung Cancer: The phase III Randomized ESOGIA-GFpC-GECp 08-02 Study. j Clin Oncol. 2016;34(13):1476-83. [Crossref]  [PubMed]
  13. hoppe S, Rainfray M, Fonck M, hoppenreys L, Blanc jF, Ceccaldi j,et al. Functional decline in older patients with cancer receiving first-line chemotherapy. j Clin Oncol. 2013; 31(31):3877-82. [Crossref]  [PubMed]
  14. Valero S, Migeot v, Bouche G, N. Raban, B. Roullet, B. Dreyfus,et al. Who needs a Comprehensive Geriatric Assessment? A French Onco-Geriatric Screening tool. j Geriatric Oncol. 2011;2:130-6. [Crossref]
  15. Overcash jA, Beckstead j, Extermann M, Cobb S. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol hematol. 2005;54:129. [Crossref]  [PubMed]
  16. Min LC, Elliott MN, Wenger NS, Saliba D. higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. j Am Geriatr Soc. 2006;54:507. [Crossref]  [PubMed]
  17. Luciani A, Ascione G, Bertuzzi C, Marussi D, Codecà C, Di Maria G, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. j Clin Oncol. 2010;28(12):2046-50. [Crossref]  [PubMed]
  18. Bellera CA, Rainfray M, Mathoulin-pélissier S, Mertens C, Delva F, Fonck M, et al.Screening older cancer patients: first evaluation of the G8 geriatric screening tool. Ann Oncol. 2012;23(8):2166-72. [Crossref]  [PubMed]
  19. Kenis C, Geeraerts A, Braes T. The Flemish version of the Triage Risk Screening Tool. Crit Rev Oncol hematolç 2006;60S:S31. [Crossref]
  20. Karuturi M, vanderWalde N, Muss h. Approach and Management of Breast Cancer in the Elderly. Clin Geriatr Med. 2016;32(1):133- 53. [Crossref]  [PubMed]
  21. Wildiers h, Kunkler I, Biganzoli L, Fracheboud j, vlastos G, Bernard-Marty C,et al: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8(12):1101-15. [Crossref]  [PubMed]
  22. Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy Ep. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. j Clin Oncol. 2010;28(12):2038-45. [Crossref]  [PubMed]  [PMC]
  23. Schonberg MA, Marcantonio ER, Ngo L, Li D, Silliman RA, McCarthy Ep. Causes of death and relative survival of older women after a breast cancer diagnosis. j Clin Oncol. 2011;29(12):1570-7. [Crossref]  [PubMed]  [PMC]
  24. Ali AM, Greenberg D, Wishart GC, pharoah p. patient and tumour characteristics, management, and age-specific survival in women with breast cancer in the East of England. Br j Cancer. 2011;104(4):564-70. [Crossref]  [PubMed]  [PMC]
  25. Patnaik jL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. j Natl Cancer Inst. 2011;103(14):1101-11. [Crossref]  [PubMed]  [PMC]
  26. Kimmick GG, Major B, Clapp j, Sloan j, pitcher B, Ballman K, et al. Using eprognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat. 2017;163(2):391-8. 27. Balducci L. Geriatric oncology. Crit Rev Oncol hematol. 2003;46(3):211-20 [Crossref]  [PubMed]
  27. Muss hB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, et al; Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph nodepositive breast cancer. jAMA. 2005;293(9):1073-81. [Crossref]  [PubMed]
  28. Rosenstock AS, Lei X, Tripathy D, hortobagyi GN, Giordano Sh, Chavez-MacGregor M. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat. 2016;157(2):339-50. [Crossref]  [PubMed]
  29. Wishart GC, Azzato EM, Greenberg DC, Rashbass j, Kearins O, Lawrence G, et al. pREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1. [Crossref]  [PubMed]  [PMC]
  30. Swain SM, Nunes R, Yoshizawa C, Rothney M, Sing Ap. Quantitative Gene Expression by Recurrence Score in ER-positive Breast Cancer, by Age. Adv Ther. 2015;32(12):1222-36. [Crossref]  [PubMed]  [PMC]
  31. hurria A, Togawa K, Mohile SG, Owusu C, Klepin hD, Gross Cp, et al. predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. j Clin Oncol. 2011;29(25):3457-65. [Crossref]  [PubMed]  [PMC]
  32. Extermann M, Boler I, Reich RR, Lyman Gh, Brown Rh, DeFelice j, et al. predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for high-Age patients (CRASh) score. Cancer. 2012;118(13):3377-86. [Crossref]  [PubMed]
  33. Muss hB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl j Med. 2009;360(20):2055-65. [Crossref]  [PubMed]  [PMC]
  34. Muss hB, polley MC, Berry DA, Liu h, Cirrincione CT, Theodoulou M, et al. Randomized Trial of Standard Adjuvant Chemotherapy Regimens versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. j Clin Oncol. 2019;37(26):2338-48. [Crossref]  [PubMed]  [PMC]
  35. Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia v, et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 2015;26(4):675-82. [Crossref]  [PubMed]
  36. Jones SE, Savin MA, holmes FA, O'Shaughnessy jA, Blum jL, vukelja S, et al. phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. j Clin Oncol. 2006;24(34):5381-7. [Crossref]  [PubMed]
  37. Freyer G, Campone M, peron j, Facchini T, Terret C, Berdah jF, et al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. Crit Rev Oncol hematol. 2011;80(3):466-73. [Crossref]  [PubMed]
  38. Brouwers B, hatse S, Dal Lago L, Neven p, vuylsteke p, Dalmasso B, et al. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget. 2016;7(21):29977-88. [Crossref]  [PubMed]  [PMC]
  39. Brollo j, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi v, et al. Adjuvant trastuzumab in elderly with hER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013;39(1):44-50. [Crossref]  [PubMed]
  40. Mackey jR, Martin M, pienkowski T, Rolski j, Guastalla jp, Sami A, TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72-80. [Crossref]  [PubMed]
  41. Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu j, Elting L, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. j Clin Oncol. 2013;31(33):4222-8. [Crossref]  [PubMed]  [PMC]
  42. von Minckwitz G, procter M, de Azambuja E, Zardavas D, Benyunes M, viale G,.AphINITY Steering Committee and Investigators. Adjuvant pertuzumab and Trastuzumab in Early hER2-positive Breast Cancer. N Engl j Med 2017;377(2):122-31. [Crossref]  [PubMed]  [PMC]
  43. Martin M, holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata h,ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in hER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688-700. [Crossref]  [PubMed]
  44. Barcenas Ch, hurvitz SA, Di palma jA, Bose R, Chien Aj, Iannotti N,CONTROL Study Investigators. Improved tolerability of neratinib in patients with hER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol 2020;31(9):1223-30. [Crossref]  [PubMed]
  45. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin j, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84. [Crossref]
  46. Dowsett M, Cuzick j, Ingle j, Coates A, Forbes j, Bliss j, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. j Clin Oncol 2010; 28(3):509-18. [Crossref]  [PubMed]
  47. Grumpelt AM, Ignatov A, Tchaikovski SN, Burger E, Costa SD, Eggemann h. Tumor characteristics and therapy of elderly patients with breast cancer. j Cancer Res Clin Oncol 2016;142:1109-16. [Crossref]  [PubMed]
  48. Bergman L, Kluck hM, van Leeuwen FE, Crommelin MA, Dekker G, hart AA, Coebergh jW. The influence of age on treatment choice and sur- vival of elderly breast cancer patients in south-eastern Netherlands: a populationbased study. Eur j Cancer. 1992;28A:1475- 80. [Crossref]  [PubMed]
  49. Cataliotti L, Buzdar AU, Noguchi S, Bines j, Takatsuka Y, petrakova K,et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the preOperative "Arimidex" Compared to Tamoxifen (pROACT) trial. Cancer. 2006;106(10):2095- 103. [Crossref]  [PubMed]
  50. Smith IE, Dowsett M, Ebbs SR, Dixon jM, Skene A, Blohmer jU, et al; IMpACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMpACT) multicenter double-blind randomized trial. j Clin Oncol. 2005;23(22):5108-16. [Crossref]  [PubMed]
  51. Ellis Mj, Suman vj, hoog j, Lin L, Snider j, prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline pAM50-based intrinsic subtype-ACOSOG Z1031. j. Clin. Oncol. 2011;29:2342-49. [Crossref]  [PubMed]  [PMC]
  52. Eiermann W, paepke S, Appfelstaedt j, Llombart-Cussac A, Eremin j, vinholes j, et al; Letrozole Neo-Adjuvant Breast Cancer Study Group. preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527-32. [Crossref]  [PubMed]
  53. Semiglazov vF, Semiglazov vv, Dashyan GA, Ziltsova EK, Ivanov vG, Bozhok AA, et al. phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptorpositive breast cancer. Cancer. 2007;110(2):244-54. [Crossref]  [PubMed]
  54. Alba E, Calvo L, Albanell j, De la haba jR, Arcusa Lanza A, Chacon jI, et al. GEICAM. Chemotherapy (CT) and hormonotherapy (hT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069- 74. [Crossref]  [PubMed]
  55. Cortazar p, Zhang L, Untch M, Mehta K, Costantino jp, Wolmark N, et al. pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. [Crossref]  [PubMed]
  56. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020;26(12):2838-48 [Crossref]  [PubMed]  [PMC]
  57. Blum jL, Flynn pj, Yothers G, Asmar L, Geyer CE jr, jacobs SA, et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABp B-46-I/USOR 07132, and NSABp B49 (NRG Oncology). j Clin Oncol. 2017;35(23):2647-55. [Crossref]  [PubMed]  [PMC]
  58. McCarthy N, Boyle F, Zdenkowski N, Bull j, Leong E, Simpson A, et al; Australia and New Zealand Breast Cancer Trials Group. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). Breast. 2014;23(2):142- 51. [Crossref]  [PubMed]
  59. von Minckwitz G, Untch M, Blohmer jU, Costa SD, Eidtmann h, Fasching pA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. j Clin Oncol. 2012;30(15):1796-804. [Crossref]  [PubMed]
  60. Untch M, Fasching pA, Konecny GE, hasmüller S, Lebeau A, Kreienberg R,et al. pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TEChNO trial of the AGO and GBG study groups. j Clin Oncol. 2011 Sep 1;29(25):3351-7. [Crossref]  [PubMed]
  61. von Minckwitz G, huang CS, Mano MS, Trastuzumab Emtansine for Residual Invasive hER2-positive Breast Cancer. N Engl j Med. 2019;380(7):617. [Crossref]  [PubMed]
  62. howie Lj, Singh h, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S, et al. Outcomes of Older Women With hormone Receptor-positive, human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA pooled Analysis. j Clin Oncol. 2019;37(36):3475-83. [Crossref]  [PubMed]
  63. Rugo hS, Turner NC, Finn RS, joy AA, verma S, harbeck N, et al. palbociclib plus endocrine therapy in older women with hR+/hER2- advanced breast cancer: a pooled analysis of randomised pALOMA clinical studies. Eur j Cancer. 2018;101:123-33. [Crossref]  [PubMed]
  64. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo hS, et al; SOLAR-1 Study Group. Alpelisib for pIK3CA-Mutated, hormone Receptor-positive Advanced Breast Cancer. N Engl j Med. 2019;380(20):1929- 40. [Crossref]  [PubMed]
  65. pritchard KI, Burris hA 3rd, Ito Y, Rugo hS, Dakhil S, hortobagyi GN,et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with hER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013;13(6):421-432.e8. [Crossref]  [PubMed]
  66. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin hCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-9. [Crossref]  [PubMed]
  67. Beuselinck B, Wildiers h, Wynendaele W, Dirix L, Kains jp, paridaens R. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology. Crit Rev Oncol hematol. 2010;75(1):70-7. [Crossref]  [PubMed]
  68. Barni S, Livraghi L, Gravina A, Martella F, D'Onofrio L, Morritti M,et al; ESEMpiO Group. Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMpiO study. j Geriatr Oncol. 2019;10(6):990-9. [Crossref]  [PubMed]
  69. Debled M, Madranges N, Mertens C, Durand M, Brouste v, Brain E, et al. First-line chemotherapy for metastatic breast cancer in patients ≥75 years: a retrospective single-centre analysis. Crit Rev Oncol hematol. 2011;80(1):171-9. [Crossref]  [PubMed]
  70. jenkins EO, Deal AM, Anders CK, prat A, perou CM, Carey LA, et al. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist. 2014;19(10):1076-83. [Crossref]  [PubMed]  [PMC]
  71. Baselga j, Swain SM. CLEOpATRA: a phase III evaluation of pertuzumab and trastuzumab for hER2-positive metastatic breast cancer. Clin Breast Cancer. 2010;10(6):489-91. [Crossref]  [PubMed]
  72. Andersson M, López-vega jM, petit T, Zamagni C, Easton v, Kamber j, et al. Efficacy and Safety of pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by vinorelbine: vELvET Cohort 2 Final Results. Oncologist. 2017;22(10):1160-8. [Crossref]  [PubMed]  [PMC]
  73. Bachelot T, Ciruelos E, Schneeweiss A, puglisi F, peretz-Yablonski T, Bondarenko I, et al; pERUSE investigators. preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for hER2- positive locally recurrent or metastatic breast cancer (pERUSE). Ann Oncol. 2019;30(5):766-73. [Crossref]  [PubMed]
  74. Wildiers h, Tryfonidis K, Dal Lago L, vuylsteke p, Curigliano G, Waters S, et al. pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with hER2-positive metastatic breast cancer (EORTC 75111- 10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018;19(3):323-36. [Crossref]  [PubMed]
  75. Rimawi M, Ferrero jM, de la haba-Rodriguez j, poole C, De placido S, Osborne CK, et al; pERTAIN Study Group. First-Line Trastuzumab plus an Aromatase Inhibitor, With or Without pertuzumab, in human Epidermal Growth Factor Receptor 2-positive and hormone Receptor-positive Metastatic or Locally Advanced Breast Cancer (pERTAIN): A Randomized, Open-Label phase II Trial. j Clin Oncol. 2018;36(28):2826-35. [Crossref]  [PubMed]
  76. verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga j, et al; EMILIA Study Group. Trastuzumab emtansine for hER2-positive advanced breast cancer. N Engl j Med. 2012;367(19):1783-91. [Crossref]  [PubMed]  [PMC]
  77. Krop IE, Kim SB, González-Martín A, LoRusso pM, Ferrero jM, Smitt M, et al; Th3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated hER2-positive advanced breast cancer (Th3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689- 99. [Crossref]  [PubMed]
  78. Montemurro F, Ellis p, Anton A, Wuerstlein R, Delaloge S, Bonneterre j, et al. Safety of trastuzumab emtansine (T-DM1) in patients with hER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur j Cancer. 2019;109:92-102. [Crossref]  [PubMed]
  79. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with hER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924-34. [Crossref]  [PubMed]  [PMC]
  80. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman j, johnston S. Lapatinib plus letrozole as first-line therapy for hER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15(2):122- 9. [Crossref]  [PubMed]  [PMC]
  81. johnston SRD, hegg R, Im SA, park Ih, Burdaeva O, Kurteva G, et al. phase III, Randomized Study of Dual human Epidermal Growth Factor Receptor 2 (hER2) Blockade With Lapatinib plus Trastuzumab in Combination With an Aromatase Inhibitor in postmenopausal Women With hER2-positive, hormone Receptor-positive Metastatic Breast Cancer: ALTERNATIvE. j Clin Oncol. 2018;36(8):741-8. [Crossref]  [PubMed]  [PMC]
  82. Balducci L, Lyman Gh. patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. j Clin Oncol. 2001;19(5):1583- 5. [Crossref]  [PubMed]
  83. hortobagyi GN, van poznak C, harker WG, Gradishar Wj, Chew h, Dakhil SR, et al. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OpTIMIZE-2 Randomized Clinical Trial. jAMA Oncol. 2017;3(7):906-12. [Crossref]  [PubMed]  [PMC]